|Project Title||Natalizumab, Efalizumab, and Progressive Multifocal Leukoencephalopathy (PML)|
Thursday, January 10, 2013
Modular program-based one-time assessment of the risk of progressive multifocal leukoencephalopathy (PML) associated with use of natalizumab and efalizumab in the Mini-Sentinel Distributed Database. Modular programs are adaptable standardized programs. Queries were executed in May 2012.
If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to email@example.com.
The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.
progressive multifocal leukoencephalopathy (PML)
2003 - 2011
Mini-Sentinel Distributed Database (MSDD)
- Vaccines, Blood & Biologics
- Devices and Radiologic Health